Clinical trials: Severe ARDS
Corona Virus Infection, Acute Respiratory Distress Syndrome
Losartan for Patients With COVID-19 Requiring Hospitalization
This is a multi-center, double-blinded study of COVID-19 infected patients requiring inpatient hospital admission randomized 1:1 to daily Losartan or placebo for 7 days or hospital discharge.
- Conditions
- Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection
- Trial name
- NCT04312009
- Testing
- Losartan
- Where
- 13 sites in United States
- Volunteers
- 205 people
- Sponsor
- University of Minnesota
Acute Respiratory Distress Syndrome, Severe Acute Respiratory Syndrome
Streptokinase Versus Unfractionated Heparin Nebulization in Severe ARDS
Background: Intra-alveolar clotting and alveolar collapse in ARDS is due to alveolar capillaries epithelial and leakage. Subsequently, collapse induces hypoxemia that is resistant to recruitment (RM).
- Trial name
- NCT03465085
- Testing
- Unfractionated heparin, Streptokinase
- Volunteers
- 60 people
- Sponsor
- Beni-Suef University
COVID, Corona Virus Infection
Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms
The study is a prospective, randomized, controlled investigation designed for comparison of two groups for the reduction of respiratory distress in a CoViD-19 population, using gammaCore Sapphire (nVNS) plus standard of care…
- Conditions
- COVID, Corona Virus Infection, Respiratory Failure, Respiratory Distress Syndrome, Adult
- Trial name
- SAVIORII (NCT04382391)
- Testing
- gammaCore® Sapphire (non-invasive vagus nerve stimulator), Standard of care therapies
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
COVID-19
Zilucoplan® in Improving Oxygenation, Short-, Longterm Outcome of COVID19 Patients With Acute Hypoxic Respiratory Failure
The study is a randomized controlled, open-label trial comparing subcutaneous Zilucoplan® with standard of care to standard of care alone.
- Trial name
- ZILU-COV (NCT04382755)
- Testing
- Zilucoplan®
- Where
- 9 sites in Belgium
- Volunteers
- 81 people
- Sponsor
- University Hospital, Ghent
ARDS, Critical Illness
Effect of PEEP on Lung Recruitment and Homogeneity Over Time in Moderate to Severe ARDS
This study evaluates the effect of airway pressure release ventilation (APRV) on lung homogeneity and recruitment in patients with moderate to severe acute respiratory distress syndrome (ARDS).
- Conditions
- ARDS, Critical Illness, Ventilator-Induced Lung Injury
- Trial name
- APRV (NCT03140579)
- Testing
- APRV
- Where
- United Kingdom
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
ARDS (Moderate or Severe), Prone Position
The PRE-VAIL Study
During the prone position, there may be an increase in intragastric pressure. The investigators focus on a scientific question: Whether reducing enteral nutrition before the prone position will benefit patients with severe…
- Conditions
- ARDS (Moderate or Severe), Prone Position, Enteral Nutrition Feeding, Intensive Care Unit (ICU) Admission
- Trial name
- NCT07176624
- Testing
- Enteral nutrition is reduced before the prone position
- Where
- China
- Volunteers
- 259 people
- Sponsor
- The First Hospital of Jilin University
ARDS (Moderate or Severe), AHRF
STimulation to Activate RespIration
Multi-center, randomized, controlled, open-label Phase 2 feasibility trial. Subjects on mechanical ventilation (MV) for acute hypoxemic respiratory failure (AHRF) with lung injury (including subjects who meet criteria for acute…
- Conditions
- ARDS (Moderate or Severe), AHRF, Mechanically Ventilated ICU Patients
- Trial name
- STARI (NCT06832306)
- Testing
- Phrenic Nerve Stimulation
- Where
- 7 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Lungpacer Medical Inc.
Corona Virus Infection, Virus Diseases
Lung Ultrasound for Assessment of Patients With Moderate to Severe Covid-19
This observational study will describe lung ultrasound (LUS) findings over time in hospitalized patients with moderate to severe Covid-19 lung disease.
- Conditions
- Corona Virus Infection, Virus Diseases, Coronaviridae Infections
- Trial name
- NCT04412551
- Where
- Sweden
- Volunteers
- 72 people
- Sponsor
- Dalarna County Council, Sweden
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
The purpose of this clinical trial is to determine the best initial non-invasive respiratory support (NIRS) strategy for adults who present to the emergency department with acute hypoxemic respiratory failure, a condition in…
- Trial name
- WINDSURFER (NCT07558265)
- Testing
- Non-Invasive Positive Pressure Ventilation, High Flow Nasal Oxygen
- Where
- 6 sites in United States
- Volunteers
- 500 people
- Sponsor
- Ohio State University
Any Condition Underlying Critical Illness
SWedish Intensive Care Biobank
The goal of this observational study is to understand the genetic and molecular risk factors for developing critical illness in adult intensive care unit (ICU) patients in Sweden.
- Trial name
- SWIC-B (NCT07582601)
- Volunteers
- 25,000 people
- Sponsor
- Uppsala University
Respiratory Distress Syndrome
High-frequency Oscillatory Ventilation (HFOV) in Preterm Infants With Severe Respiratory Distress Syndrome (RDS)
Respiratory distress syndrome (RDS) is common in preterm infants born at less than 32 weeks gestation; surfactant and mechanical ventilation have been the standard treatment.
- Trial name
- NCT01496508
- Testing
- mechanical ventilation (SLE 5000, Servo-i-Maquet)
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Zhengzhou Children's Hospital, China
Lung Cancer, Severe ARDS
Immune Checkpoints in COPD
The aim of this study is to investigate the mechanisms underlying the complex interaction between Chronic obstructive pulmonary disease (COPD) and lung cancer.
- Conditions
- Lung Cancer, Severe ARDS, Asthma, Copd
- Trial name
- CP-COPD (NCT04654104)
- Testing
- check immune check points
- Where
- 2 sites in Italy
- Volunteers
- 80 people
- Sponsor
- University of Catanzaro
Severe Acute Respiratory Syndrome
The Interaction Between Severe Acute Respiratory Distress Syndrome Viral Proteins and Monocytes
Severe acute respiratory syndrome (SARS) is a new threat to public health since November, 2002. The SARS is highly contagious and is believed to be transmitted by person-to-person through droplet and direct contact.
- Trial name
- NCT00172263
- Testing
- blood sampling
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
ARDS, Human, COVID
Senicapoc in COVID-19 Patients With Severe Respiratory Insufficiency
SARS-CoV-2, one of a family of human coronaviruses, was initially identified in December 2019 in Wuhan city. This new coronavirus causes a disease that has now been named COVID-19.
- Trial name
- COVIPOC (NCT04594668)
- Testing
- Senicapoc
- Where
- 4 sites in Denmark
- Volunteers
- 46 people
- Sponsor
- University of Aarhus
Corona Virus Infection, Acute Respiratory Distress Syndrome
Losartan for Patients With COVID-19 Not Requiring Hospitalization
This is a multi-center, double-blinded study of COVID-19 infected patients randomized 1:1 to daily losartan or placebo for 10 days or treatment failure (hospital admission).
- Conditions
- Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection
- Trial name
- NCT04311177
- Testing
- Losartan
- Where
- 4 sites in United States
- Volunteers
- 117 people
- Sponsor
- University of Minnesota
Acute Respiratory Distress Syndrome, SARS-CoV-2
Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19
Evaluation of the safety, tolerability, and pharmacokinetics of PLN-74809 in participants with acute respiratory distress syndrome (ARDS) associated with at least severe COVID-19
- Trial name
- NCT04565249
- Testing
- PLN-74809
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Pliant Therapeutics, Inc.
COVID-19 Acute Respiratory Distress Syndrome
Efficacy of Canrenone as add-on Treatment in Moderate to Severe ARDS in COVID-19
The main aim of the study is to estimate the potential efficacy of i.v. canrenone as add-on therapy on maximal medical treatment versus maximal medical treatment alone in treating moderate-to-severe ARDS due to SARS-CoV-2.
- Trial name
- MINECRAFT (NCT04977960)
- Testing
- Potassium Canrenoate
- Volunteers
- 180 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Severe Acute Respiratory Syndrome (ARDS) Secondary to SARS-COV-2 Infection
An Observational Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications
This observational study will collect data from patients treated with siltuximab program for treatment of SARS-CoV-2 infection complicated with serious respiratory complications.
- Trial name
- SISCO (NCT04322188)
- Where
- Italy
- Volunteers
- 220 people
- Sponsor
- A.O. Ospedale Papa Giovanni XXIII
Corona Virus Infection, ARDS Due to Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2
Early-initiated High Flow Oxygen Therapy vs Conventional Oxygen Therapy Among Patients With ARDS in the Course of SARS-CoV2 Pneumonia.
The aim of the study is to compare two methods of oxygen therapy in patients with acute respiratory distress syndrome in the course of SARS-CoV2 pneumonia.
- Conditions
- Corona Virus Infection, ARDS Due to Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2, Oxygen Deficiency
- Trial name
- NCT05197686
- Testing
- Oxygen theraphy with high flow nasal cannule, Oxygen theraphy with mask with reservoir
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Pomeranian Medical University Szczecin
Acute Respiratory Distress Syndrome, COVID-19
Predictors of Severe COVID-19 Outcomes
This is a longitudinal, multi-center, observational study collecting diverse biological measurements and clinical and epidemiological data for the purpose of enabling a greater understanding of the onset of severe outcomes…
- Trial name
- PRESCO (NCT04388813)
- Where
- 8 sites in United States
- Volunteers
- 494 people
- Sponsor
- Verily Life Sciences LLC